https://doi.org/10.4081/reumatismo.2023.1544
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
Submitted: 22 December 2022
Accepted: 19 April 2023
Published: 17 July 2023
Accepted: 19 April 2023
Abstract Views: 761
PDF: 439
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The objective of this study was to evaluate biological disease-modifying anti-rheumatic drugs (bDMARDs) survival in several therapy courses of patients affected by psoriatic arthritis (PsA) and to compare tumor necrosis factor inhibitors (TNFi) and non-TNFi retention rates. A total of 241 bDMARD therapy courses (155 TNFi drugs, 65 anti-interleukin (IL)-17 drugs, and 21 anti-IL12/23) were analyzed. Bivariate analyses were performed to assess the presence of demographic and clinical features, as well as comorbidities, associated with bDMARD discontinuation in TNFi and non-TNFi groups. In the bivariate analyses of TNFi and non-TNFi groups, we found a lower age at the start of TNFi therapy in the former group [46 years, interquartile range (IQR) 45-54 vs 50.5 years, IQR 42-61; p=0.004] as well as a lower proportion of patients with skin psoriasis (65.8% vs 88.4%; p<0.001). Survival analysis showed no significant differences between TNFi and non-TNFi groups. Cox regression found fibromyalgia as a predictor of drug failure [hazard ratio (HR) 3.40, confidence interval (CI) 1.92-6.03; p<0.001] and first-line bDMARDs as a protective factor (HR 0.46, CI 0.25-0.88; p=0.019). Lastly, among TNFi courses, fibromyalgia was associated with drug suspension (HR 6.52, CI 3.16-13.46; p<0.001), while only a trend of significance for skin psoriasis as a risk factor for drug failure was shown (HR 2.38, CI 1.00-5.66, p=0.05). This study provides information about clinical and demographic factors associated with retention rates of bDMARDs from a real-life, single-center cohort of PsA patients.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 545-68.
DOI: https://doi.org/10.1016/j.rdc.2015.07.001
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
DOI: https://doi.org/10.1016/0049-0172(73)90035-8
Madland TM, Apalset EM, Johannessen AE, Rossebö B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in western norway. J Rheumatol 2005; 32: 1918-22.
FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers 2021; 7: 59.
DOI: https://doi.org/10.1038/s41572-021-00293-y
Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in european/north american dermatology clinics. J Am Acad Dermatol 2013; 69: 729-35.
DOI: https://doi.org/10.1016/j.jaad.2013.07.023
Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop 2014; 5: 537-43.
DOI: https://doi.org/10.5312/wjo.v5.i4.537
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-70.
DOI: https://doi.org/10.1056/NEJMra1505557
Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006; 33: 210-2.
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021; 41: 275-84.
DOI: https://doi.org/10.1007/s00296-020-04775-2
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79: 700-12.
DOI: https://doi.org/10.1136/annrheumdis-2020-217163
Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 2014; 41: 2315-22.
DOI: https://doi.org/10.3899/jrheum.140882
Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open 2020; 6: e001117.
DOI: https://doi.org/10.1136/rmdopen-2019-001117
Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020; 79: 760-70.
DOI: https://doi.org/10.1136/annrheumdis-2019-216653
Gossec L, Smolen JS, Ramiro S, De Wit M, Cutolo M, Dougados M, et al. european league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75: 499-510.
DOI: https://doi.org/10.1136/annrheumdis-2015-208337
Adami G, Idolazzi L, Benini C, Fracassi E, Carletto A, Viapiana O, et al. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement. Reumatismo 2023; 75(1). DOI: https://doi.org/10.4081/reumatismo.2023.1559.
DOI: https://doi.org/10.4081/reumatismo.2023.1559
Mease PJ, Smolen JS, Behrens F, Nash P, Leage SL, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79: 123-31.
DOI: https://doi.org/10.1136/annrheumdis-2019-215386
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18: 465-79.
DOI: https://doi.org/10.1038/s41584-022-00798-0
Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does age matter in psoriatic arthritis? A narrative review. J Rheumatol 2022; 49: 1085-91.
DOI: https://doi.org/10.3899/jrheum.210349
Cook MJ, Bellou E, Bowes J, Sergeant JC, O’Neill TW, Barton A, et al. The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology (Oxford) 2018; 57: 2172-82.
DOI: https://doi.org/10.1093/rheumatology/key224
Navarini L, Costa L, Tasso M, Chimenti MS, Currado D, Fonti GL, et al. Retention rates and identification of factors associated with TNFi, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clin Rheumatol 2020; 39: 2663-70.
DOI: https://doi.org/10.1007/s10067-020-05027-1
Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, et al. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatol Int 2020; 40: 263-72.
DOI: https://doi.org/10.1007/s00296-019-04416-3
McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open 2022; 8: e002074.
DOI: https://doi.org/10.1136/rmdopen-2021-002074
Lindström U, Giuseppe DD, Delcoigne B, Glintborg B, Möller B, Ciurea A, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the eurospa collaboration. Ann Rheum Dis 2021; 80: 1410-8.
DOI: https://doi.org/10.1136/annrheumdis-2021-220097
Xie Y, Liu Y, Liu Y. Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials. Dermatol Ther 2021; 34: e14926.
DOI: https://doi.org/10.1111/dth.14926
Vincken NLA, Balak DMW, Knulst AC, Welsing PMJ, van Laar JM. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology (Oxford) 2022; 61: 4232-44.
DOI: https://doi.org/10.1093/rheumatology/keac129
Favalli EG, Marchesoni A, Balduzzi S, Montecucco C, Lomater C, Crepaldi G, et al. Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the italian lorhen registry. Arthritis Rheumatol 2019; 71.
Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L, et al. One-year effectiveness, retention rate and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicentre study. Expert Opin Biol Ther 2020; 20: 813-21.
DOI: https://doi.org/10.1080/14712598.2020.1761957
Lorenzin M, Carletto A, Foti R, Chimenti MS, Semeraro A, Costa L, et al. Effectiveness and safety of secukinumab in naïve or tnf-inhibitors failure psoriatic arthritis patients in real life: a 24-months prospective multicenter study. Ann Rheum Dis 2020; 79: 730.
DOI: https://doi.org/10.1136/annrheumdis-2020-eular.3702
Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the nationwide danish danbio registry. Arthritis Rheum 2011; 63: 382-90.
DOI: https://doi.org/10.1002/art.30117
Alonso S, Villa I, Fernández S, Martín JL, Charca L, Pino M, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in cantabria and asturias study. Front Med 2021; 8: 679009.
DOI: https://doi.org/10.3389/fmed.2021.679009
Højgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B, et al. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using danish health care registers. Rheumatology (Oxford) 2018; 57: 1651-60.
DOI: https://doi.org/10.1093/rheumatology/key140
Prior-Español A, Sánchez-Piedra C, Campos J, Manero FJ, Pérez-García C, Bohórquez C, et al. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry. Sci Rep 2021; 11: 11091.
DOI: https://doi.org/10.1038/s41598-021-90442-w
Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P, et al. Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med 2020; 7: 288.
DOI: https://doi.org/10.3389/fmed.2020.00288
Generali E, Scirè CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Isr Med Assoc J 2016; 18: 203-8.
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, et al. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the spanish BIOBADASER registry. Rheumatol Int 2019; 39: 509-15.
DOI: https://doi.org/10.1007/s00296-018-4177-z
Lorenzin M, Ortolan A, Cozzi G, Calligaro A, Favaro M, Del Ross T, et al. Predictive factors for switching in patients with psoriatic arthritis undergoing antiTNF, anti-il12/23 or anti-il17 drugs: A fifteenyear monocentric real-life study. Ann Rheum Dis 2021; 80: 4569-80.
DOI: https://doi.org/10.1007/s10067-021-05799-0
Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rødevand E, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013; 72: 1840-4.
DOI: https://doi.org/10.1136/annrheumdis-2012-203018
Reddy SM, Crean S, Martin AL, Burns MD, Palmer JB. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 2016; 35: 2955-66.
DOI: https://doi.org/10.1007/s10067-016-3425-4
Manfreda V, Chimenti MS, Canofari C, Esposito M, Perricone R, Bianchi L, et al. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. Clin Exp Rheumatol 2020; 38: 581-2.
Ballegaard C, Højgaard P, Dreyer L, Cordtz R, Jørgensen TS, Skougaard M, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res 2018; 70: 592-9.
DOI: https://doi.org/10.1002/acr.23333
Lubrano E, Scriffignano S, Fatica M, Triggianese P, Conigliaro P, Perrotta FM, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther 2023; 10: 589-9.
DOI: https://doi.org/10.1007/s40744-023-00535-3
Dougados M, Lucas J, Desfleurs E, Claudepierre P, Goupille P, Ruyssen-Witrand A, et al. Factors associated with secukinumab (sec) retention in axial spondyloarthritis (axspa): results of the french retrospective study forsya. RMD Open 2023; 9: e002802.
DOI: https://doi.org/10.1136/rmdopen-2022-002802
Iannone F, Salaffi F, Fornaro M, Di Carlo M, Gentileschi S, Cantarini L, et al. Influence of baseline modified rheumatic disease comorbidity index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis in real-world settings. Eur J Clin Invest 2018; 48: e13013.
DOI: https://doi.org/10.1111/eci.13013
Favalli EG, Biggioggero M, Becciolini A, Crotti C, Sinigaglia L. Comorbidities affect the retention rate but not the clinical response in a cohort of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors. Ann Rheum Dis 2018; 77: 928.
DOI: https://doi.org/10.1136/annrheumdis-2018-eular.4412
Biggioggero M, Mesina F, Favalli EG. The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int 2019; 2019: 6107217.
DOI: https://doi.org/10.1155/2019/6107217
Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 2018; 57: 158-63.
DOI: https://doi.org/10.1093/rheumatology/kex387
Chimenti MS, Conigliaro P, Caso F, Costa L, Ortolan A, Triggianese P, et al. Long‐term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clin Rheumatol 2022; 41: 75-84.
DOI: https://doi.org/10.1007/s10067-021-05874-6
Chimenti MS, Ortolan A, Lorenzin M, Triggianese P, Talamonti M, Costa L, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol 2018; 37: 397-405.
DOI: https://doi.org/10.1007/s10067-017-3953-6
How to Cite
Ferrito, M., Cincinelli, G., Manara, M., Di Taranto, R., Favalli, E., & Caporali, R. (2023). Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients. Reumatismo, 75(2). https://doi.org/10.4081/reumatismo.2023.1544
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- S. Maddali Bongi, A. Del Rosso, M. Matucci Cerinic, Rheumatologic rehabilitation: towards recommendations , Reumatismo: Vol. 66 No. 3 (2014)
- M. Manara, M. Varenna, A clinical overview of bone marrow edema , Reumatismo: Vol. 66 No. 2 (2014)
- G.L. Erre, A. Tocco, R. Faedda, A. Cossu, A. Carcassi, Diagnostic and prognostic value of antibodies to cyclic citrullinated peptide (Anti-CCP) in rheumatoid arthritis , Reumatismo: Vol. 56 No. 2 (2004)
- P. Sarzi- Puttini, F. Atzeni, E. Lubrano, Complementary medicine in rheumatoid arthritis , Reumatismo: Vol. 57 No. 4 (2005)
- M. Manara, A. Bortoluzzi, M. Favero, I. Prevete, C.A. Scirè, G. Bianchi, C. Borghi, M. A. Cimmino, G. M. D'Avola, G. Desideri, G. Di Giacinto, M. Govoni, W. Grassi, A. Lombardi, M. Marangella, M. Matucci Cerinic, G. Medea, R. Ramonda, A. Spadaro, L. Punzi, G. Minisola, Italian Society of Rheumatology recommendations for the management of gout , Reumatismo: Vol. 65 No. 1 (2013)
- C. Botsios, P. Ostuni, S. Todesco, Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience , Reumatismo: Vol. 57 No. 1 (2005)
- D. Bonanno, R. Fedele, P. Minciullo, P. Quattrocchi, B. Ferlazzo, Idiopathic hypereosinophilic syndrome associated with rheumatoid arthritis A case report , Reumatismo: Vol. 55 No. 3 (2003)
- P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula, The treatment of recurrent uveitis with TNFα inhibitors , Reumatismo: Vol. 56 No. 3 (2004)
- F.M. Mariani, A. Alunno, F. Carubbi, C. Ferri, A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib , Reumatismo: Vol. 76 No. 2 (2024)
- C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi, Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis , Reumatismo: Vol. 59 No. 1 (2007)
<< < 17 18 19 20 21 22 23 24 25 26 > >>
You may also start an advanced similarity search for this article.
